A Durable Response to Low-Dose Afatinib After Progression on Osimertinib in Advanced Epidermal Growth Factor Receptor (EGFR) L861Q-Mutated Lung Adenocarcinoma: A Case Report. - Higashi T; Araya T; Ueda T; Hara R; Takato H; Kita T (Cureus, 2026)